Precise 3D QCT to Monitor Osteoporosis Therapy

精确的 3D QCT 监测骨质疏松症治疗

• 批准号: 6662712
• 负责人: THOMAS F LANG
• 金额: $ 26.84万
• 依托单位: IMAGE ANALYSIS, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6662712
• 关键词: alendronate; bioimaging /biomedical imaging; bone density; bone imaging /visualization /scanning; clinical research; computed axial tomography; computer program /software; diagnosis quality /standard; hip; human subject; image processing; osteoporosis; parathyroid hormones; pathologic process; patient monitoring device; phantom model; prognosis; spine

DESCRIPTION (provided by applicant):The growing number of women receiving drug treatment for osteoporosis underscores the need for sensitive methods to monitor therapy. Because it permits selective assessment of the trabecular and cortical bone, which may respond differently to disease and therapy, quantitative computed tomography (QCT) is well-suited to this purpose. However, the ability of QCT to resolve therapy- or disease-induced changes in bone mineral density (BMD) is limited by variable precision errors. These precision errors mostly relate to the operator-dependence of current techniques, which involve manual slice selection and region of interest placement. In our Phase I Grant, we have addressed this problem by developing and demonstrating the feasibility of an image registration algorithm which aligns serial images and uses the resulting 3D transformation to map a baseline region into the same volume of the follow-up image. As we have documented in the Phase I Final Report, this fast and automated approach yields precision errors in vivo of 1.0 mg/cc and 0.9 mg/cc for spinal and proximal femoral trabecular BMD measurements respectively. In this application, we propose to develop and commercialize a prototype software package which will combine diagnostic 3D QCT BMD measurements with our new approach for highly reproducible longitidunal measurements. PROPOSED COMMERCIAL APPLICATION: We will provide commercial CT imaging centers with a powerful set of tools which they can use to compete in the bone mineral density measurement market. The diagnostic measurement component will allow CT scanners to measure bone mineral density in the spine and hip in bone regions comparable to those measured by DXA. Moreover, the high reproducibility of our technique will permit CT centers to offer a method for monitoring therapy effects which will be superior to DXA.

描述（由申请人提供）：接受骨质疏松症的药物治疗的妇女人数越来越强，强调了对治疗敏感方法的需求。由于它允许对小梁和皮质骨的选择性评估，这可能对疾病和治疗的反应不同，因此定量计算机断层扫描（QCT）非常适合此目的。但是，QCT解决骨矿物质密度（BMD）的治疗或疾病诱导的变化的能力受到可变精度误差的限制。这些精度误差主要与当前技术的运算符依赖性有关，该技术涉及手动切片选择和关注区域的位置。在我们的阶段I授予中，我们通过开发和证明图像注册算法的可行性来解决这个问题，该算法将串行图像对齐并使用所得的3D变换将基线区域映射到相同的后续图像中。正如我们在第一阶段的最终报告中所记录的那样，这种快速自动化的方法分别在1.0 mg/cc和0.9 mg/cc的体内产生精度误差，分别用于股骨和股骨近端小梁BMD测量值。在此应用程序中，我们建议开发和商业化一个原型软件包，该软件包将结合诊断3D QCT BMD测量结果以及我们的新方法，以进行高度可重现的纵向测量。 拟议的商业应用：我们将为商业CT成像中心提供一套强大的工具，可以用来在骨矿物质密度测量市场中竞争。 诊断测量成分将使CT扫描仪能够测量脊柱中的骨矿物质密度，并在骨区中与DXA测量的骨骼区域的髋关节。 此外，我们技术的高可重现性将使CT中心能够提供一种监测治疗效果的方法，该方法将优于DXA。